Literature DB >> 11525794

Increased post-traumatic survival of neurons in IL-6-knockout mice on a background of EAE susceptibility.

J Fisher1, T Mizrahi, H Schori, E Yoles, H Levkovitch-Verbin, S Haggiag, M Revel, M Schwartz.   

Abstract

Axonal injury initiates a process of neuronal degeneration, with resulting death of neuronal cell bodies. We show here that in C57BL/6J mice, previously shown to have a limited ability to manifest a post-traumatic protective immunity, the rate of neuronal survival is increased if IL-6 is deficient during the first 24 hours after optic nerve injury. Immunocytochemical staining preformed 7 days after the injury revealed an increased number of activated microglia in the IL-6-deficient mice compared to the wild-type mice. In addition, IL-6-deficient mice showed an increased resistance to glutamate toxicity. These findings suggest that the presence of IL-6 during the early post-traumatic phase, at least in mice that are susceptible to autoimmune disease development, has a negative effect on neuronal survival. This further substantiates the contention that whether immune-derived factors are beneficial or harmful for nerve recovery after injury depends on the phenotype of the immune cells and the timing and nature of their dialog with the damaged neural tissue.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11525794     DOI: 10.1016/s0165-5728(01)00342-3

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  13 in total

1.  Macrophage population dynamics within fetal mouse fibroblast cultures derived from C57BL/6, CD-1, CF-1 mice and interleukin-6 and granulocyte colony stimulating factor knockout mice.

Authors:  Neil C Talbot; Max Paape; Eun Jung Sohn; Wesley M Garrett
Journal:  In Vitro Cell Dev Biol Anim       Date:  2004 Jul-Aug       Impact factor: 2.416

Review 2.  Inflammation as a causative factor in the aetiology of Parkinson's disease.

Authors:  P S Whitton
Journal:  Br J Pharmacol       Date:  2007-03-05       Impact factor: 8.739

Review 3.  Mitochondrial dysfunction and oxidative stress in Parkinson's disease.

Authors:  Isaac G Onyango
Journal:  Neurochem Res       Date:  2007-10-17       Impact factor: 3.996

4.  Neuroprotection and progenitor cell renewal in the injured adult murine retina requires healing monocyte-derived macrophages.

Authors:  Anat London; Elena Itskovich; Inbal Benhar; Vyacheslav Kalchenko; Matthias Mack; Steffen Jung; Michal Schwartz
Journal:  J Exp Med       Date:  2011-01-10       Impact factor: 14.307

5.  Oral administration of the KATP channel opener diazoxide ameliorates disease progression in a murine model of multiple sclerosis.

Authors:  Noemí Virgili; Juan F Espinosa-Parrilla; Pilar Mancera; Andrea Pastén-Zamorano; Javier Gimeno-Bayon; Manuel J Rodríguez; Nicole Mahy; Marco Pugliese
Journal:  J Neuroinflammation       Date:  2011-11-02       Impact factor: 8.322

6.  Interleukin-6 Deficiency Attenuates Retinal Ganglion Cell Axonopathy and Glaucoma-Related Vision Loss.

Authors:  Franklin D Echevarria; Cathryn R Formichella; Rebecca M Sappington
Journal:  Front Neurosci       Date:  2017-05-31       Impact factor: 4.677

7.  Proinflammatory cytokines in a mouse model of central retinal artery occlusion.

Authors:  Michal Kramer; S Dadon; M Hasanreisoglu; Y Monselise; B R Avraham; A Feldman; I Eldar; D Weinberger; N Goldenberg-Cohen
Journal:  Mol Vis       Date:  2009-05-01       Impact factor: 2.367

8.  Erratum: The two sides of cytokine signaling and glaucomatous optic neuropathy.

Authors:  Ping Huang; Samuel Shao-Min Zhang; Chun Zhang
Journal:  J Ocul Biol Dis Infor       Date:  2009-09-09

9.  The two sides of cytokine signaling and glaucomatous optic neuropathy.

Authors:  Ping Huang; Samuel Shao-Min Zhang; Chun Zhang
Journal:  J Ocul Biol Dis Infor       Date:  2009-07-01

Review 10.  Interleukin-6, a major cytokine in the central nervous system.

Authors:  María Erta; Albert Quintana; Juan Hidalgo
Journal:  Int J Biol Sci       Date:  2012-10-25       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.